Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Kaufmann

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Chemical Biology & Drug Design|February 11, 2012
Prediction of HIV-1 protease/inhibitor affinity using RosettaLigandGordon Lemmon, Kristian Kaufmann, Jens Meiler
Journal of Molecular Modeling|May 13, 2010
A physical model for PDZ-domain/peptide interactionsKristian Kaufmann, Nicole Shen, Laura Mizoue, et al.
ACS Chemical Neuroscience|July 11, 2012
Y95 and E444 interaction required for high-affinity S-citalopram binding in the human serotonin transporterSteven Combs, Kristian Kaufmann, Julie R Field, et al.
Bioorganic & Medicinal Chemistry Letters|August 7, 2013
Discovery and SAR of a novel series of GIRK1/2 and GIRK1/4 activatorsSusan J Ramos-Hunter, Darren W Engers, Kristian Kaufmann, et al.
Bioorganic & Medicinal Chemistry Letters|July 11, 2013
Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitorsWandong Wen, Wenjun Wu, Ian M Romaine, et al.
ACS Chemical Neuroscience|April 17, 2015
Development and validation of a thallium flux-based functional assay for the sodium channel NaV1.7 and its utility for lead discovery and compound profilingYu Du, Emily Days, Ian Romaine, et al.
The Journal of Biological Chemistry|July 7, 2011
A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transportL Keith Henry, Hideki Iwamoto, Julie R Field, et al.
ACS Chemical Neuroscience|June 5, 2013
ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in miceKristian Kaufmann, Ian Romaine, Emily Days, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Chemical Biology & Drug Design|February 11, 2012
Prediction of HIV-1 protease/inhibitor affinity using RosettaLigandGordon Lemmon, Kristian Kaufmann, Jens Meiler
Journal of Molecular Modeling|May 13, 2010
A physical model for PDZ-domain/peptide interactionsKristian Kaufmann, Nicole Shen, Laura Mizoue, et al.
ACS Chemical Neuroscience|July 11, 2012
Y95 and E444 interaction required for high-affinity S-citalopram binding in the human serotonin transporterSteven Combs, Kristian Kaufmann, Julie R Field, et al.
Bioorganic & Medicinal Chemistry Letters|August 7, 2013
Discovery and SAR of a novel series of GIRK1/2 and GIRK1/4 activatorsSusan J Ramos-Hunter, Darren W Engers, Kristian Kaufmann, et al.
Bioorganic & Medicinal Chemistry Letters|July 11, 2013
Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitorsWandong Wen, Wenjun Wu, Ian M Romaine, et al.
ACS Chemical Neuroscience|April 17, 2015
Development and validation of a thallium flux-based functional assay for the sodium channel NaV1.7 and its utility for lead discovery and compound profilingYu Du, Emily Days, Ian Romaine, et al.
The Journal of Biological Chemistry|July 7, 2011
A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transportL Keith Henry, Hideki Iwamoto, Julie R Field, et al.
ACS Chemical Neuroscience|June 5, 2013
ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in miceKristian Kaufmann, Ian Romaine, Emily Days, et al.
Pageof 1